TG THERAPEUTICS INC. - COMMON STOCK

35.07

22-November-24 16:44:58

15 minutes delayed

Stocks

+0.52

+1.51%

Today's range

33.71 - 35.32

ISIN

N/A

Source

NASDAQ

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

05 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 Jul 2024 09:58:20 By NetDania Notify
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 Jun 2024 07:50:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

03 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

31 May 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

28 May 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

01 May 2024 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

30 Apr 2024 16:55:29 By Nasdaq GlobeNewswire
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

18 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

08 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

28 Feb 2024 07:00:01 By Nasdaq GlobeNewswire
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

27 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.